More Rx, Dx Firms Join Forces On Companion Diagnostics, But Obstacles To European Market Remain
This article was originally published in The Pink Sheet Daily
Executive Summary
A "highly regionalized payer environment, with variable health technology assessment requirements and an associated reimbursement time lag" is to blame for much of the problem, French industry exec says.